|Picking the best CRISPR-Cas9 targets for functional gene knockout: a machine learning algorithm based on both specificity and functionality|
Shawn McClelland, Emily M. Anderson, Žaklina Strezoska, Elena Maksimova, Annaleen Vermeulen, Steve Lenger, Tyler Reed, and Anja van Brabant Smith Dharmacon, now part of GE Healthcare, 2650 Crescent Drive, Suite #100, Lafayette, CO 80026, US
The CRISPR-Cas9 system has the potential to significantly advance basic and applied research.
|Scaffold design, function and over-expression of lentiviral-based microRNAs|
Angela Schoolmeesters, Melissa L. Kelley, Annaleen Vermeulen, Anja Smith, *Mayya Shveygert, *Xin Zhou, *Robert Blelloch Dharmacon, now part of GE Healthcare, 2650 Crescent Drive, Suite #100, Lafayette, CO 80026, USA
Here we describe the strategy for scaffold design, the importance of an optimal promoter, and demonstrate gene target down-regulation from the over-expression of lentiviral microRNA mimics.
|Homology-directed repair with Dharmacon™ Edit-R™ CRISPR-Cas9 and single-stranded DNA oligos|
John A. Schiel, Eldon T. Chou, Maren Mayer, Emily M. Anderson , and Anja van Brabant Smith | Dharmacon, now part of GE Healthcare, 2650 Crescent Drive, Suite #100, Lafayette, CO 80026, US
Here we demonstrate how to perform lipid based transfections for homology directed repair using DharmaFECT Duo, CRISPR-Cas9 reagents and, synthetic DNA donor oligos.
|Human iPSC-derived hepatocytes and cardiomyocytes for drug toxicity testing|
AnnandRR; Vardaro R; Hamilton B; Akakira R; Tamura K; Yoshida S; Lin YC; Toyoda D; Kogami H; Okuda Y; Watanabe T; Inamura M
Human iPS-derived hepatocytes (ReproHepato™) and cardiomyocytes (ReproCardio 2™) are useful for in vitro toxicity assays.
|Human iPSC-derived hepatocytes ReproHepateTM for CYP assay and drug toxicity testing |
Annand R; Akahira R; Tamura K; Inamura M
We developed iPSC-derived hepatocytes and used them for CYP induction and cytotoxicity assays.
|Fighting Blindness with 3D-NET "Drug Discovery & Development of Novel Eye Therapeutics"|
Pilar Ventosa-Andrés, Nils Ohnesorge, Yolanda Fernández, Yolanda Alvarez and Breandán Kennedy
3D-NET, “Drug Discovery & Development of Novel Eye Therapeutics”, is a new European research consortium of industry and academic partners focusing efforts to enhance the discovery and development of drugs targeting ocular pathologies that lead to blindness.
|"In-vitro studies on hydroxamic acid- CT DNA binding" |
In vitro studies of five the interaction between five different derivatives of hydroxamic acids, N-phenyl 2,4dichloro phenoxybutyro, N-m-tolyl 2,4 dichlorophenoxyglutero, N-m-tolyl-4-chlorophenoxyaceto, N-m-chloro-phenyl-tertiarybutylbenzo and N-p-tolyl-iso-valero hydroxamic acids and calf thymus DNA was investigated under simulated physiological condition.
|Metabolism of Eight Model Pharmaceutical Compounds in Rat and Human HepatoPac Versus Liver Microsomes and Suspension Hepatocyte Platforms|
Julius O. Enoru, William DeMaio, Adiba Watanyar, Kenneth Draper, Amanda Moore & Okey Ukairo
This poster presents our comparative metabolite profiling analysis of eight model pharmaceutical compounds with various biotransformation reactions using a functionally stable model of primary hepatocytes [micropatterned co-cultures (MPCCs)] in parallel with the traditional liver microsomal and suspension hepatocyte systems.
|Automated Fluorescence Detection and Imaging of RNA Species in Live Cells|
Paul Held, Victor Koong, Don Weldon, Peter Banks
This poster describes the detection and quantification of RNA species in Live cells through automated imaging.